Bell Bank Cuts Stock Position in Bristol Myers Squibb Company $BMY

Bell Bank trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 78.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,246 shares of the biopharmaceutical company’s stock after selling 15,021 shares during the period. Bell Bank’s holdings in Bristol Myers Squibb were worth $229,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Bath Savings Trust Co grew its position in Bristol Myers Squibb by 2.3% during the fourth quarter. Bath Savings Trust Co now owns 8,743 shares of the biopharmaceutical company’s stock valued at $472,000 after acquiring an additional 198 shares during the last quarter. Albert D Mason Inc. raised its stake in shares of Bristol Myers Squibb by 3.0% during the fourth quarter. Albert D Mason Inc. now owns 7,236 shares of the biopharmaceutical company’s stock worth $390,000 after acquiring an additional 213 shares in the last quarter. CVA Family Office LLC lifted its holdings in shares of Bristol Myers Squibb by 2.6% in the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 223 shares during the last quarter. MSH Capital Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 2.9% in the 3rd quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company’s stock valued at $362,000 after purchasing an additional 223 shares in the last quarter. Finally, Bell & Brown Wealth Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 0.5% during the 3rd quarter. Bell & Brown Wealth Advisors LLC now owns 42,691 shares of the biopharmaceutical company’s stock valued at $1,925,000 after purchasing an additional 224 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on BMY shares. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. HSBC boosted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Finally, Guggenheim restated a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus price target of $61.41.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 data for Camzyos (mavacamten) in adolescents — SCOUT‑HCM showed efficacy and safety in teens with symptomatic obstructive hypertrophic cardiomyopathy, supporting a potential label expansion and added addressable market for an established cardiovascular product. This is a clear pipeline upside that could lift long‑term revenue expectations. Bristol Myers Presents Positive SCOUT‑HCM Results
• Positive Sentiment: Supportive real‑world/switch data for Cobenfy — Phase 4/open‑label switch results indicate symptom stability and acceptable tolerability when patients transition from other oral atypical antipsychotics to Cobenfy (xanomeline + trospium). These data help the schizophrenia franchise by reducing switching risk and may aid uptake. Open‑Label Switch Study for Cobenfy
• Neutral Sentiment: Investor write‑ups and buy theses highlight valuation and dividend appeal — recent articles argue BMY’s P/E and forward metrics, plus dividend yield and upcoming ex‑dividend timing, make the stock attractive for income/value investors, which can support a base under the share price but may not trigger rapid re‑rating. Is BMY a Good Stock to Buy?
• Neutral Sentiment: Ex‑dividend timing noted — coverage points out BMY goes ex‑dividend soon, which can attract short‑term dividend seekers but has limited fundamental impact. BMY Looks Like A Good Stock, Ex‑Dividend Soon
• Neutral Sentiment: Mixed analyst sentiment — roughly 60% of covering analysts show mixed ratings even though the consensus price target (~$63) implies modest upside; this split can cap near‑term momentum until clearer fundamentals emerge. Mixed Analyst Sentiment
• Negative Sentiment: Fundamental headwinds remain from prior earnings and guidance dynamics — recent quarterly EPS missed expectations and FY‑2026 guidance is below some street forecasts, which keeps near‑term valuation under pressure and helps explain downward stock moves despite clinical positives. (Background company filings and recent results.)

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $58.59 on Monday. The firm has a market cap of $119.62 billion, a PE ratio of 16.98, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company’s fifty day simple moving average is $58.82 and its two-hundred day simple moving average is $52.27.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue was up 1.3% on a year-over-year basis. During the same period last year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is currently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.